Drug Approval | December 06, 2023
Zydus receives final approval from the USFDA for Ivabradine Tablets
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Total transaction value of the divestment is Rs. 3,660 million
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
New Board of Directors and management team at Suven Pharma also appointed
Subscribe To Our Newsletter & Stay Updated
